1: Riva N, Gentile F, Cerri F, Gallia F, Podini P, Dina G, Falzone YM, Fazio R, Lunetta C, Calvo A, Logroscino G, Lauria G, Corbo M, Iannaccone S, Chiò A, Lazzerini A, Nobile-Orazio E, Filippi M, Quattrini A. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022 Jan 25:awab285. doi: 10.1093/brain/awab285.
2: Pugliese R, Sala R, Regondi S, Beltrami B, Lunetta C. Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces. J Neurol. 2022 Jan 21:1–12. doi: 10.1007/s00415-022-10971-w.
3: Poletti B, Solca F, Carelli L, Diena A, Colombo E, Torre S, Maranzano A, Greco L, Cozza F, Lizio A, Ferrucci R, Girotti F, Verde F, Morelli C, Lunetta C, Silani V, Ticozzi N. Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders. Neurology. 2021 Nov 2;97(18):e1835-e1846. doi: 10.1212/WNL.0000000000012774.
5: Greco LC, Lizio A, Casiraghi J, Sansone VA, Tremolizzo L, Riva N, Solca F, Torre S, Ticozzi N, Filippi M, Silani V, Poletti B, Lunetta C. A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. J Neurol. 2021 Aug 19. doi: 10.1007/s00415-021-10753-w.
6: Cattaneo M, Jesus P, Lizio A, Fayemendy P, Guanziroli N, Corradi E, Sansone V, Leocani L, Filippi M, Riva N, Corcia P, Couratier P, Lunetta C. The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):41-47. doi: 10.1136/jnnp-2021-326184.
7: Dalla Bella E, Bersano E, Antonini G, Borghero G, Capasso M, Caponnetto C, Chiò A, Corbo M, Filosto M, Giannini F, Spataro R, Lunetta C, Mandrioli J, Messina S, Monsurrò MR, Mora G, Riva N, Rizzi R, Siciliano G, Silani V, Simone I, Sorarù G, Tugnoli V, Verriello L, Volanti P, Furlan R, Nolan JM, Abgueguen E, Tramacere I, Lauria G. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain. 2021 Oct 22;144(9):2635-2647. doi: 10.1093/brain/awab167.
8: Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, Matà S, Mazzini L, Sabatelli M, Siciliano G, Simone IL, Sorarù G, Toriello A, Trojsi F, Vedovello M, D'Ovidio F, Filippi M, Calvo A; and EDARAVALS Study Group. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020 Nov;267(11):3258-3267. doi: 10.1007/s00415-020-09993-z.
9: Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X.
10: Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, Appel SH, Chiò A. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017 Jun 1;74(6):660-667. doi: 10.1001/jamaneurol.2016.6179. PMID: 28384752; PMCID: PMC5822215.
